Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

SPECTATOR: Perfusion Monitoring Before, During and After Lower Extremity Revascularization With Laser Speckle Contrast Imaging (SPECTATOR)

9. september 2026 oppdatert av: Joost R. van der Vorst, MD, PhD, Leiden University Medical Center
This study aims to evaluate the feasibility of Laser Speckle Contrast Imaging for perioperative perfusion assessment of the lower extremity before, during, and after revascularization.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

Rationale: Lower extremity arterial disease (LEAD) arises from atherosclerotic obstruction in the lower limbs, which in turn leads to symptoms ranging from intermittent claudication to ulcer formation. As the disease progresses, patients often require revascularization to achieve limb salvage.

To improve prediction of clinical outcomes following revascularization, various techniques have been introduced to quantify tissue perfusion. Among these, near-infrared fluorescence imaging with indocyanine green (ICG NIRF) has gained attention. This method combines a laser light source with intravenous ICG administration to visualize perfusion. Although ICG NIRF appears promising for guiding revascularization strategies and predicting outcomes, its invasive nature, requiring dye injection, limits its use in outpatient settings.

Consequently, there is a need for a non-invasive, real-time technique that enables rapid and straightforward perfusion assessment. One such promising approach is laser speckle contrast imaging (LSCI). Therefore, this study aims to evaluate the feasibility of LSCI for perioperative perfusion assessment of the lower extremity before, during, and after revascularization.

Objective:The primary objective of this study is to evaluate the feasibility of laser speckle contrast imaging (LSCI) for monitoring perfusion in the lower extremities during and following revascularization.

Secondary objectives include correlating LSCI findings with the temperature of the patient's foot, comparing LSCI with near-infrared fluorescence imaging using indocyanine green (ICG NIRF) and exploring potential quantitative approaches such as the assessment of blood flow pulsatility.

Study design: This study will be a prospective cohort study. Study population: Adult patients undergoing a revascularization of the lower extremity due to peripheral artery disease. Such revascularization can be bypass surgery, thrombo-endarterectomy (TEA), or endovascular percutaneous transluminal angioplasty (PTA).

Intervention: Patients will undergo peri-operative and post-operative LSCI.

Main study parameters/endpoints: The main study parameters are the quantified perfusion parameters measured with LSCI.

Nature and extent of the burden and risks associated with participation. The use of the LSCI device is not expected to cause any adverse effects, as it employs a low-intensity near-infrared laser to illuminate the skin. The photon energy and illumination power used are well below levels that could cause tissue damage and are therefore considered safe for human skin. All measurements are performed alongside standard assessments or routine outpatient clinic appointments. The intraoperative measurement does not extend the duration of the surgical procedure. Given the short duration of each measurement (5-10 seconds), no additional burden on patients is anticipated.

Studietype

Observasjonsmessig

Registrering (Antatt)

30

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • South Holland
      • Leiden, South Holland, Nederland, 2333ZA
        • Rekruttering
        • Leiden University Medical Center
        • Ta kontakt med:
        • Ta kontakt med:
        • Underetterforsker:
          • Indy Planting, MD
        • Hovedetterforsker:
          • Joost van der Vorst, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

The population of this study will undergo a revascularization of the lower extremity due to peripheral artery disease. Such revascularization can be thrombo-endarterectomy (TEA), or endovascular percutaneous transluminal angioplasty (PTA).

Beskrivelse

Inclusion Criteria:

  • Scheduled for lower-extremity revascularization
  • Undergoing pre- and postoperative indocyanine near-infrared fluorescence perfusion measurements

Exclusion Criteria:

Any condition that the investigator considers to be potentially jeopardizing the patient's wellbeing or the study objectives

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Fontaine 2
Measurement with LSCI device
Fontaine 3
Measurement with LSCI device
Fontaine 4
Measurement with LSCI device

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To assess the feasibility and the quantification of laser speckle contrast imaging for monitoring of perfusion of the lower extremities during and following revascularization
Tidsramme: From pre-operative baseline measurement through the 6-week postoperative follow-up visit
Feasibility
From pre-operative baseline measurement through the 6-week postoperative follow-up visit

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Correlation of pre-, intra- and postsurgery laser speckle contrast imaging (LSCI) findings with the pre-, intra- and post-temperature of the patient's foot
Tidsramme: From pre-operative baseline measurement through the 6-week postoperative follow-up visit
Temperature
From pre-operative baseline measurement through the 6-week postoperative follow-up visit
Comparative analysis of LSCI with standard of care near-infrared fluorescence imaging using ICG
Tidsramme: From pre-operative baseline measurement through the postoperative ICG-measurement
ICG
From pre-operative baseline measurement through the postoperative ICG-measurement
Exploration of quantitative approaches to LSCI analysis, including assessment of blood flow pulsatility
Tidsramme: From pre-operative baseline measurement through the 6-week postoperative follow-up visit
From pre-operative baseline measurement through the 6-week postoperative follow-up visit
Correlation of quantified LSCI recordings to clinical outcomes.
Tidsramme: 6 weeks postoperative
6 weeks postoperative
Effect of anesthesia induction on quantified LSCI perfusion values
Tidsramme: Intraoperative, pre-anesthesia induction and post-anesthesia induction (prior to revascularization)
Exploratory comparison of quantified laser speckle perfusion units (LSPU) in the plantar region of interest measured before versus after induction of anesthesia (prior to revascularization), to assess whether anesthesia induction is associated with a change in LSCI-derived perfusion values. Measurement setup and non-invasive LSCI acquisition procedure are unchanged from the pre-anesthesia measurement; no additional burden or risk to participants.
Intraoperative, pre-anesthesia induction and post-anesthesia induction (prior to revascularization)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. september 2026

Primær fullføring (Antatt)

1. mai 2028

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

23. april 2026

Først innsendt som oppfylte QC-kriteriene

23. april 2026

Først lagt ut (Faktiske)

30. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

14. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere